GENE ONLINE|News &
Opinion
Blog

2022-03-09| Licensing

Novartis Bets $1.5 Billion on Voyager’s AAVs

by Joy Lin
Share To

Novartis has announced that it is licensing Voyager Therapeutics’ adeno-associated virus (AAV) technology to deliver gene therapies for neurological diseases.

Under the deal, Novartis will initially license Voyager’s AAV capsids for three undisclosed targets in the CNS, and could opt to license two more. 

Novartis will pay Voyager $54 million upfront and up to $37.5 million in licensing fees for the first three targets. If Novartis chooses to add the other two targets, it will have to pay Voyager $18 million per target selected, and a $12.5 million exercise fee to match a capsid to the selected target. Voyager could also earn up to $1.5 billion in development and commercial milestones, as well as single-digit royalties for product sales. 

Related Article: Sio Gene Therapies Touts Positive Safety and Biomarker Data for GM1 Gangliosidosis Candidate

 

Voyager’s Capsid Discovery Platform

 

Voyager claims that its RNA-driven capsid discovery platform  could create AAVs capable of penetrating the blood-brain barrier with greater efficacy. Studies on non-human primates also suggested the capsids would also improve gene uptake by cells in the brain and spinal cord, and could also be directed to cardiac muscle. 

Voyager is screening for more AAV9 and AAV5 capsid variants that can better target specific populations of cells such as glial cells. 

Related Article: Voyager Therapeutics’ Novel AAV Capsid Tech for Gene Therapy Attracts Pfizer’s Investment

 

Interests and Exits  

 

Many companies have shown interest in Voyager’s viral shells. Pfizer announced last October that it will license Voyager’s capsids for use with one neurologic and one cardiovascular target. The deal was estimated to be worth $630 million. 

However, other deals have not gone as smoothly. In 2019, Neurocrine Biosciences partnered with Voyager in a $1.865 billion deal for four neuroscience targets including Parkinson’s disease and Friedreich’s ataxia. By August 2021, Neurocrine had pulled out of the Parkinson’s portion of the agreement, after safety issues from that program led to an FDA hold. 

Even earlier, Sanofi’s Genzyme bet $100 million to license Voyager’s programs which covered Parkinson’s, Friedreich’s ataxia and Hungtington’s disease, but had dropped the three programs by 2019. In 2020, Voyager lost another partner in Abbvie after the latter decided to drop partnerships over Alzheimer’s disease and Parkinson’s. 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
M&A
Pfizer Acquires Global Blood Therapeutics and its sickle cell disease expertise for $5.4 billion
2022-08-09
LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!